|Bid||27.81 x 1800|
|Ask||27.91 x 1200|
|Day's range||27.30 - 28.47|
|52-week range||4.04 - 32.18|
|Beta (5Y monthly)||2.82|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
MacroGenics (NASDAQ: MGNX) shares are falling 17.3% as of 12:15 p.m. EST on Friday. The drop coincides with the release of the company's presentations at the annual American Society of Clinical Oncology meeting, and it follows a surge in its share price earlier this month. The ASCO conference is highly anticipated, and historically, investors have bought shares in stocks presenting at the conference ahead of time, hoping for a short-term pop.
Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. Here's what you need to know about the businesses behind these recent stock market run-ups before thinking about adding them to a portfolio you'd like to manage successfully.
After MacroGenics (NASDAQ: MGNX) updated investors on its clinical-stage drug pipeline and current financial position, its shares are soaring 171% as of 12:45 am EDT Wednesday. After the market's closing bell on Tuesday, the biotech company's management said it remains on track to report final overall survival (OS) data for the phase 3 SOPHIA study of margetuximab in HER2-positive metastatic breast cancer this year. If the data is solid, MacroGenics believes it could get a Food and Drug Administration decision as soon as December 2020.
MacroGenics (MGNX) delivered earnings and revenue surprises of 9.90% and 84.12%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
ROCKVILLE, Md. (AP) _ MacroGenics Inc. (MGNX) on Tuesday reported a loss of $30.4 million in its fourth quarter. On a per-share basis, the Rockville, Maryland-based company said it had a loss of 62 cents. The results topped Wall Street expectations.
MacroGenics (MGNX) delivered earnings and revenue surprises of 4.21% and -19.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics (MGNX) delivered earnings and revenue surprises of 32.29% and -39.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?